US › Healthcare

Invivyd Inc. (IVVD)

US · Healthcare · Biotechnology

$0.62-7.47%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$14.3M

Revenue YoY

+21.2%

Net profit

$-44.4M

EPS

$-0.14

EPS estimate

$-0.15

Net margin

-310.8%

EPS came in at -0.14 against a street estimate of -0.15 — a beat of 6.7%.

Key statistics

Market cap

$190.4M

Forward P/E

44.6

P/B

1.50

Book value

$0.61

EPS (TTM)

$-0.33

52-week high

$3.07

52-week low

$0.53

50-day MA

$0.82

200-day MA

$1.30

Beta

0.95

Analyst view

Analysts rate Invivyd Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $10.00.

Shareholding

Insiders

7.16%

Institutions

86.94%

Largest institutional holders

Fund	Stake
Jupiter Topco LLC	11.59%
HHG PLC	11.23%
Bvf Inc	9.56%
Maverick Capital Ltd	6.44%
Perceptive Advisors LLC	6.27%
BlackRock Inc	5.47%
Vanguard Capital Management, LLC	3.56%
M28 Capital Management LP	3.14%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Invivyd Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.